Spondyloarthritis & psoriatic arthritis
Effectiveness of treat-to-target tapering of TNF inhibitors for psoriatic arthritis and axial spondyloarthritis in the Netherlands: 24-month follow-up of the DRESS-PS trial
Primary result · Low disease activity at 24 months, proportionResult — go to the resultAdjusted difference 5 % 95% CI −15 to 24Authors' conclusion
Treat-to-target tapering of TNF inhibitors remains effective and safe for the maintenance of low disease activity for up to 2 years in patients with psoriatic arthritis and axial spondyloarthritis.
Study context
- Population
- Patients aged 16 years and older with PsA or axSpA and stable low disease activity for at least 6 months, Sint Maartenskliniek, the Netherlandsof 122 trial patients
- Participants
- 114 patients
- Comparison
- Original treat-to-target TNFi tapering vs treat-to-target without tapering
- Interventionn = 79
- Controln = 35reference
- Primary endpoint
- Difference between original groups in proportion with low disease activity, adjusted for stratification factors, vs non-inferiority margin of 20%
- Follow-up
- Up to 24 months
Methodological details12-month observational extension, original trial open-label, non-inferiority, non-inferiority margin 20%, treat-to-target, shared decision making
- 12-month observational extension
- Original trial open-label
- Non-inferiority
- Non-inferiority margin 20%
- Treat-to-target
- Shared decision making
Primary result
Low disease activity at 24 months, proportion
Adjusted difference
5 %
95% CI −15 to 24
P = 0.64
Events by treatment group
Controlvs Intervention
adjusted difference 5 % (95% CI −15 to 24); P = 0.64
Non-inferiority margin 20 as printed, not drawn
As reported in the abstract
Safety
| Outcome | Intervention | Control | Difference (%) (CI) | P value | |
|---|---|---|---|---|---|
| At least one adverse event · up to 24 months | 99% | 89% | 10 (−1 to 21) | P = 0.060 | |
| −100102030Difference, % (linear scale) |
Adverse events of special interest: infections and injection site reactions
- No significant differences between groups
Original publication
Effectiveness of treat-to-target tapering of TNF inhibitors for psoriatic arthritis and axial spondyloarthritis in the Netherlands: 24-month follow-up of the DRESS-PS trial. Lancet Rheumatol. Published 24 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →